초기 1상모집 예정

Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

연구 개요

This feasibility trial studies the efficacy of administering iberdomide (CC-220) as a priming agent prior to leukapheresis in patients with relapsed/refractory multiple myeloma (RRMM) who are already planned for standard-of-care CAR-T therapy. Giving iberdomide before CAR-T may improve T cell fitness which may improve CAR-T expansion kinetics and response after infusion.

스폰서: 협력: BMS
적응증: Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
중재: Iberdomide, CAR-T Leukapheresis, CAR-T Infusion
목표 등록: 22명
시작일: 2026-07-01
완료(예정): 2031-07-01
등록번호: NCT07727668 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.